EUVIMEDEUVIMED entdecken
Crossref

Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance

Dian-Jeng Li, Tien-Wei Hsu, Te-Chang Changchien, Yi-Ya Fang, Fu-Chi Yang, Hung-Yi Lin, Chih-Sung Liang

Journal of Affective Disorders · 2026-11 · 412 · 122106

DOI: 10.1016/j.jad.2026.122106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2026-11. Verfasst von Dian-Jeng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Addiction Science, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan; Department of Nursing, Meiho University, Ping…. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antidepressive Agents, Substance-Related Disorders, Ketamine. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Little is known about esketamine's effectiveness for patients with major depressive disorder (MDD) comorbid substance use disorders (SUD). METHODS We conducted a retrospective cohort study using the TriNetX US Collaborative Network, including adults aged ≥18 years with MDD. Three propensity-score-matched (1:1) cohorts were defined based on treatment: esketamine, antidepressant-only, and repetitive transcranial magnetic stimulation (rTMS). We calculated relative risks (RRs) to compare the prevalence of substance use disorder (SUD) across these groups. Among esketamine users, we employed Cox proportional hazards models to analyze clinical outcomes-including self-harm, suicide attempt, hospitalization, emergency visits, and mortality-comparing those with and without SUD from the first esketamine prescription. RESULTS Esketamine users (n = 30,670) showed higher risks of comorbid SUD across all categories versus matched antidepressant and rTMS patients. Compared to the antidepressant group, the highest risks were for hallucinogen (RR 2.41, 95% CI 1.87-3.09), opioid (RR 2.26, 95% CI 2.14-2.37), and stimulant (RR 2.17, 95% CI 2.01-2.34). Elevated risks were also observed versus the rTMS group, with the highest for opioid (RR 3.70, 95% CI 3.14-4.35). Within the esketamine cohort, the presence of comorbid SUD was associated with higher risks for self-harm (HR 2.99, 95% CI 2.29-3.91), suicide attempt (HR 2.13, 95% CI 1.59-2.85), emergency visits (HR 1.78, 95% CI 1.70-1.85), hospitalization (HR 1.70, 95% CI 1.63-1.77), and mortality (HR 1.12, 95% CI 1.04-1.21). CONCLUSION Esketamine prescription bias toward MDD patients with comorbid SUD underscores the need for enhanced monitoring and specialized care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Major Depressive DisorderAntidepressive AgentsSubstance-Related DisordersKetaminePractice Patterns, Physicians'HumansRetrospective StudiesFemaleComorbidityAdultMaleMiddle AgedTranscranial Magnetic StimulationSuicide, AttemptedHospitalizationProportional Hazards ModelsUnited States

Stichwörter der Autor:innen

EsketamineMajor depressive disorderMortalitySubstance use disorderSuicide attempt

Substanzen

Antidepressive AgentsEsketamineKetamine

Autor:innen und Institutionen

  • Department of Addiction Science, Kaohsiung Municipal Kai-Syuan Psychiatric Hospital, Kaohsiung, Taiwan; Department of Nursing, Meiho University, Pingtung, Taiwan. Electronic address: edcrfvm45@hotmail.com.
  • Department of Psychiatry, E-DA Dachang Hospital, I-Shou University, Kaohsiung, Taiwan; Department of Psychiatry, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, I-Shou Unive…
  • Department of Psychiatry, E-DA Hospital, I-Shou University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan. Electronic address: tcchangchien@gmail.com.
  • Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiun…
  • Department of Neurology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan. Electronic address: fuji-yang@yahoo.com.tw.
  • Department of Psychiatry, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, Taipei, Taiwan. Electronic address: hun…

Zitieren

APA

Li, D. J., Hsu, T. W., Changchien, T. C., Fang, Y. Y., Yang, F. C., Lin, H. Y., & Liang, C. S. (2026). Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance. Journal of Affective Disorders, 412, 122106. https://doi.org/10.1016/j.jad.2026.122106

Vancouver

Li DJ, Hsu TW, Changchien TC, Fang YY, Yang FC, Lin HY, et al. Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance. Journal of Affective Disorders. 2026;412:122106. doi:10.1016/j.jad.2026.122106

BibTeX
@article{Li2026,
  author = {Li, Dian-Jeng and Hsu, Tien-Wei and Changchien, Te-Chang and Fang, Yi-Ya and Yang, Fu-Chi and Lin, Hung-Yi and Liang, Chih-Sung},
  title = {Prescribing bias and adverse outcomes of esketamine in major depression comorbid substance},
  journal = {Journal of Affective Disorders},
  year = {2026},
  volume = {412},
  pages = {122106},
  doi = {10.1016/j.jad.2026.122106}
}
Kostenlos starten →